These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 4688656)

  • 1. Evidence for the suppression of the development of cytotoxic lymphoid cells in tumor immunized mice.
    Martin WJ; Esber E; Wunderlich JR
    Fed Proc; 1973 Feb; 32(2):173-9. PubMed ID: 4688656
    [No Abstract]   [Full Text] [Related]  

  • 2. Suppressed development of cytotoxic lymphoid cells in tumor-immunized mice.
    Martin WJ; Wunderlich JR; Macdonald J
    Isr J Med Sci; 1973 Mar; 9(3):324-31. PubMed ID: 4710040
    [No Abstract]   [Full Text] [Related]  

  • 3. Functional capacity of cytotoxic lymphoid cells.
    Wunderlich JR; Martin WJ; Macdonald J; Fletcher F
    Natl Cancer Inst Monogr; 1972 Dec; 35():243-9. PubMed ID: 4676543
    [No Abstract]   [Full Text] [Related]  

  • 4. Mechanism of blocking by hyperimmune serum of lymphocyte-mediated cytolysis of allogeneic tumor cells.
    Todd RF; Stulting RD; Berke G
    Cancer Res; 1973 Dec; 33(12):3203-8. PubMed ID: 4760536
    [No Abstract]   [Full Text] [Related]  

  • 5. Functional efficiency of antitumor cytotoxic lymphoid cells.
    Wunderlich JR; Martin WJ; Macdonald J
    Isr J Med Sci; 1973 Mar; 9(3):317-23. PubMed ID: 4710039
    [No Abstract]   [Full Text] [Related]  

  • 6. Generation of lytic and proliferative lymphoid clones to syngeneic tumor: in vitro and in vivo studies.
    Rosenstein M; Rosenberg SA
    J Natl Cancer Inst; 1984 May; 72(5):1161-5. PubMed ID: 6609266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of lymphocyte-mediated cytotoxicity against allogeneic tumor cells by concanavalin A in vivo.
    Anaclerio A; Waterfield JD; Möller G
    J Immunol; 1974 Sep; 113(3):870-5. PubMed ID: 4413847
    [No Abstract]   [Full Text] [Related]  

  • 8. Production of tumor-specific antibody in the xenogeneic host: use of blocking antibody.
    Weiner RS; Hubbard JD; Mardiney MR
    J Natl Cancer Inst; 1972 Oct; 49(4):1063-70. PubMed ID: 4117316
    [No Abstract]   [Full Text] [Related]  

  • 9. Non-reactivity of incompatible lymphoid cells from f1 modified radiation chimeras to host tumour cells in vitro.
    Grant CK; Ilbery PL
    Biomedicine; 1973 Feb; 19(2):56-60. PubMed ID: 4581503
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytotoxic action of spleen lymphocytes to simian virus 40-induced tumor cells.
    Egusa K
    Acta Med Okayama; 1973 Aug; 27(3):107-23. PubMed ID: 4357059
    [No Abstract]   [Full Text] [Related]  

  • 11. Temperature control of lymphocyte-mediated cytotoxicity in vitro.
    Berke G; Sullivan KA
    Transplant Proc; 1973 Mar; 5(1):421-3. PubMed ID: 4695950
    [No Abstract]   [Full Text] [Related]  

  • 12. Generation of long-term T-lymphoid cell lines with specific cytotoxic reactivity for a syngeneic murine lymphoma.
    Eberlein TJ; Rosenstein M; Spiess PJ; Rosenberg SA
    J Natl Cancer Inst; 1982 Jul; 69(1):109-16. PubMed ID: 6980314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo.
    Truitt RL; Shih CY; Lefever AV; Tempelis LD; Andreani M; Bortin MM
    J Immunol; 1983 Oct; 131(4):2050-8. PubMed ID: 6194224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lectin-dependent cell-mediated cytotoxicity: assessment of cytotoxic reactivity following challenge with syngeneic tumors.
    Laux DC; Parker BM; DiSciullo SO; Petrarca MA; McAllister CG
    J Natl Cancer Inst; 1984 Mar; 72(3):667-72. PubMed ID: 6583449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of established Friend virus leukemia by statolon. IV. Role of humoral antibody in the development of a dormant infection.
    Wheelock EF; Toy ST; Caroline NL; Sibal LR; Fink MA; Beverley PC; Allison AC
    J Natl Cancer Inst; 1972 Mar; 48(3):665-73. PubMed ID: 5062046
    [No Abstract]   [Full Text] [Related]  

  • 16. Tumor neutralization, immunotherapy, and chemoimmmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro.
    Cheever MA; Kempf RA; Fefer A
    J Immunol; 1977 Aug; 119(2):714-8. PubMed ID: 886192
    [No Abstract]   [Full Text] [Related]  

  • 17. The occurrence of tow types of cytotoxic lymphoid cells in mice immunised with allogeneic tumour cells.
    Denham S; Grant CK; Hall JG; Alexander P
    Transplantation; 1970 Apr; 9(4):366-82. PubMed ID: 5534104
    [No Abstract]   [Full Text] [Related]  

  • 18. The occurrence of two types of cytotoxic lymphoid cells in mice immunised with allogeneic tumour cells.
    Denham S; Grant CK; Hall JG; Alexander P
    Transplantation; 1970 Apr; 9(4):366-82. PubMed ID: 5534489
    [No Abstract]   [Full Text] [Related]  

  • 19. Sensitivity of target cells to the cytotoxic effects of lymphocytes induced by interferon.
    Slavina EG; Leneva NV; Svet-Moldavsky GJ
    Folia Biol (Praha); 1974; 20(4):231-7. PubMed ID: 4370360
    [No Abstract]   [Full Text] [Related]  

  • 20. Expression of multiple unique rejection antigens on murine leukemia BALB/c RLmale symbol1 and the role of dominant Akt antigen for tumor escape.
    Matsuo M; Wada H; Honda S; Tawara I; Uenaka A; Kanematsu T; Nakayama E
    J Immunol; 1999 Jun; 162(11):6420-5. PubMed ID: 10352255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.